15 million yuan! Another pharmaceutical company to complete the financing, plus code innovative drug field.

"Pharmaceutical Network Industry Dynamics" August 19 news, Shenzhen Olive Biopharmaceutical Technology Co., Ltd. (hereinafter referred to as "Olive Pharma") received 15 million yuan angel round financing, by Junsheng Investment Fund investment.
it is understood that the current round of funds will be used for the development of the company's preclinical projects.
data show that Olive Medicine is a pioneering small molecule drug therapy developer, based on Traditional Chinese medicine and natural plants, the use of modern biomedical technology, around aging and related metabolic disorders and other diseases, mining with the potential to prevent and control the pioneering small molecule drug therapy.
incomplete statistics, olive medicine in the field of health care this year a total of 34 financing.
years, under the reform of the domestic drug review and approval system, the pace of innovation drug review and approval has accelerated and the pace of listing has accelerated.
background, many pharmaceutical and biological enterprises in the field of code-added innovative drugs, strengthen research and development investment, and even open diversified financing channels, with a view to achieving rapid development.
industry points out that financing and research and development are important for innovative pharmaceutical companies.
generally, it takes ten years to develop a new drug, more than a few decades, and faces challenges such as high research and development costs, high risks, and long return cycles.
most of China's pharmaceutical companies are small and medium-sized, there are difficulties in research and development investment, once a huge investment, if the project fails, the loss will be very heavy.
from the public information, in addition to olive medicine, there are a number of pharmaceutical companies have completed financing, plus code innovative drug field.
, on August 5th, the antibacterial new drug research and development company Alliance Pharmaceuticals announced the completion of nearly 300 million yuan of round D financing.
This round of financing will be jointly invested by Huagai Capital, China National Pharmaceutical COFCO Medical Industry Fund and Qingke Capital Management, and the funds will be mainly used to promote and expand clinical pipeline research and development, as well as the full independent commercialization of the Chinese market.
Deqi Pharmaceuticals has announced the completion of a $97 million round of C-round financing, which will be used to continue to consolidate and strengthen research and development pipelines, promote clinical development of hematoma and solid tumor products, while enhancing commercial operations in the Asia-Pacific market and continuing to enhance the capacity of early drug independent research and development.
July 27, Huaping Investment, the world's leading private equity firm, led a round B financing of 1.2 billion yuan for Shanghai Haihe Pharmaceutical Research and Development Co., Ltd.
funding for this round of financing will be used to help Sea and drugs accelerate the development and launch of several new anti-tumor drugs worldwide, providing patients with safer and more effective drug options.
, according to incomplete statistics, at least 97 financings have been completed in china's biopharmaceutical and technology sectors since the first half of this year, and some innovative biopharmaceutical companies at different stages of development have received considerable financial support.
For example, in June, Python completed a $100 million round B financing that will be used to continue to drive clinical research on CAR-T therapy JWCAR029, further expand research and development pipelines and commercialize preparation to support new product launches.
, at least 12 Chinese biopharmaceutical companies have made successful IPOs since the first half of this year, seven of which have chosen to list on the Hong Kong Stock Exchange or the Board, according to public information.
and in these 12 companies, many are in the development of cancer, autoimmune disease drugs, such as Kangfang Bio, No cheng Jianhua, Tianyi Bio, Zexi Pharmaceuticals and so on.
, in the second half of this year, domestic innovative drugs are about to enter an intensive market period.
the Lilac Garden Insight database, at least 11 new drugs, including seven home-grown innovative drugs, will be approved in the second half of this year, according to the Lilac Garden Insight database.
can be foreseen that in the future, with the joint efforts of regulatory authorities, industrialists, capital institutions and so on, domestic innovative drugs will accelerate into the golden decade, and the innovative pharmaceutical industry will show a vigorous development trend.
.